Temat: "Programmed Cell Death 1 Receptor" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling.
Autorzy:: Li T; Department of Gynecology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310009, People's Republic of China.; Zhejiang Provincial Clinical Research Center for Obstetrics and Gynecology, Hangzhou, China.
Niu M; Cancer Center, Shanxi Bethune Hospital, Shanxi Academy of Medical Science, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China.
Zhou J; Department of Gynecology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310009, People's Republic of China.; Zhejiang Provincial Clinical Research Center for Obstetrics and Gynecology, Hangzhou, China.
Wu K; Cancer Center, Shanxi Bethune Hospital, Shanxi Academy of Medical Science, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China. .
Yi M; Department of Breast Surgery, College of Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou, 310000, People's Republic of China. mingyi_.; Pokaż więcej
Źródło:: Cell communication and signaling : CCS [Cell Commun Signal] 2024 Mar 12; Vol. 22 (1), pp. 179. Date of Electronic Publication: 2024 Mar 12.
Typ publikacji:: Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:: Antibodies, Bispecific*/therapeutic use
Neoplasms*/therapy
Programmed Cell Death 1 Receptor*/antagonists & inhibitors
Humans ; B7-H1 Antigen ; Signal Transduction ; Tumor Microenvironment

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Magnetic resonance imaging-based approaches for detecting the efficacy of combining therapy following VEGFR-2 and PD-1 blockade in a colon cancer model.
Autorzy:: Xu X; Medical Imaging Center, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
Ma M; Department of Radiology, The Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, 510080, China.
Ye K; Medical Imaging Center, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
Zhang D; Medical Imaging Center, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
Chen X; Medical Imaging Center, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
Wu J; Medical Imaging Center, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
Mo X; Medical Imaging Center, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
Xiao Z; Medical Imaging Center, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China. .; The Guangzhou Key Laboratory of Molecular and Functional Imaging for Clinical Translation, Jinan University, Guangzhou, 510632, China. .
Shi C; Medical Imaging Center, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China. .; The Guangzhou Key Laboratory of Molecular and Functional Imaging for Clinical Translation, Jinan University, Guangzhou, 510632, China. .
Luo L; Medical Imaging Center, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China. .; The Guangzhou Key Laboratory of Molecular and Functional Imaging for Clinical Translation, Jinan University, Guangzhou, 510632, China. .; Pokaż więcej
Źródło:: Journal of translational medicine [J Transl Med] 2024 Feb 23; Vol. 22 (1), pp. 198. Date of Electronic Publication: 2024 Feb 23.
Typ publikacji:: Journal Article
MeSH Terms:: Colonic Neoplasms*/diagnostic imaging
Colonic Neoplasms*/drug therapy
Programmed Cell Death 1 Receptor*/antagonists & inhibitors
Immune Checkpoint Inhibitors*/therapeutic use
Animals ; Humans ; Mice ; Diffusion Magnetic Resonance Imaging/methods ; Magnetic Resonance Imaging/methods ; Mice, Inbred C57BL ; Vascular Endothelial Growth Factor Receptor-2/antagonists & inhibitors

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Inhibitor of PD-1/PD-L1: a new approach may be beneficial for the treatment of idiopathic pulmonary fibrosis.
Autorzy:: Tan J; Department of Respiratory Medicine, The Second Hospital of Jilin University, Changchun, China.
Xue Q; Hospital of Jilin University, Changchun, China.
Hu X; Department of Respiratory Medicine, The Second Hospital of Jilin University, Changchun, China.
Yang J; Department of Respiratory Medicine, The Second Hospital of Jilin University, Changchun, China. .; Pokaż więcej
Źródło:: Journal of translational medicine [J Transl Med] 2024 Jan 23; Vol. 22 (1), pp. 95. Date of Electronic Publication: 2024 Jan 23.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Programmed Cell Death 1 Receptor*
Idiopathic Pulmonary Fibrosis*
Humans ; B7-H1 Antigen ; Contraindications ; Immune Tolerance

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Structural and biological characterization of pAC65, a macrocyclic peptide that blocks PD-L1 with equivalent potency to the FDA-approved antibodies.
Autorzy:: Rodriguez I; Department of Organic Chemistry, Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, Krakow, 30-387, Poland.
Kocik-Krol J; Department of Organic Chemistry, Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, Krakow, 30-387, Poland.
Skalniak L; Department of Organic Chemistry, Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, Krakow, 30-387, Poland.
Musielak B; Department of Organic Chemistry, Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, Krakow, 30-387, Poland.
Wisniewska A; Department of Organic Chemistry, Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, Krakow, 30-387, Poland.
Ciesiołkiewicz A; Department of Bioorganic Chemistry, Faculty of Chemistry, Wrocław University of Science and Technology, Wybrzeże Wyspiańskiego 27, Wrocław, 50-370, Poland.
Berlicki Ł; Department of Bioorganic Chemistry, Faculty of Chemistry, Wrocław University of Science and Technology, Wybrzeże Wyspiańskiego 27, Wrocław, 50-370, Poland.
Plewka J; Department of Organic Chemistry, Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, Krakow, 30-387, Poland.
Grudnik P; Malopolska Centre of Biotechnology, Jagiellonian University, Gronostajowa 7a, Krakow, 30-387, Poland.
Stec M; Department of Clinical Immunology, Institute of Pediatrics, Jagiellonian University Medical College, Wielicka 265, Krakow, 30-663, Poland.
Siedlar M; Department of Clinical Immunology, Institute of Pediatrics, Jagiellonian University Medical College, Wielicka 265, Krakow, 30-663, Poland.
Holak TA; Department of Organic Chemistry, Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, Krakow, 30-387, Poland.
Magiera-Mularz K; Department of Organic Chemistry, Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, Krakow, 30-387, Poland. .; Pokaż więcej
Źródło:: Molecular cancer [Mol Cancer] 2023 Sep 07; Vol. 22 (1), pp. 150. Date of Electronic Publication: 2023 Sep 07.
Typ publikacji:: Letter; Research Support, Non-U.S. Gov't
MeSH Terms:: B7-H1 Antigen*
Programmed Cell Death 1 Receptor*
Humans ; Antibodies, Monoclonal/pharmacology ; Immune Checkpoint Inhibitors ; Peptides/pharmacology

Raport

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials.
Autorzy:: Chu X; Department of Oncology, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Kaifu District, Changsha, 410008, China.
Tian W; Department of Oncology, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Kaifu District, Changsha, 410008, China.
Wang Z; Department of Oncology, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Kaifu District, Changsha, 410008, China.
Zhang J; Department of Oncology, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Kaifu District, Changsha, 410008, China.
Zhou R; Department of Oncology, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Kaifu District, Changsha, 410008, China. .; Xiangya Lung Cancer Center, Xiangya Hospital, Central South University, Changsha, 410008, China. .; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008, Hunan Province, P.R. China. .; Pokaż więcej
Źródło:: Molecular cancer [Mol Cancer] 2023 Jun 08; Vol. 22 (1), pp. 93. Date of Electronic Publication: 2023 Jun 08.
Typ publikacji:: Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:: Programmed Cell Death 1 Receptor*
Neoplasms*/drug therapy
Humans ; B7-H1 Antigen ; Immunotherapy/methods ; Combined Modality Therapy ; Receptors, Immunologic

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Evaluation of the possible association of PDCD-1 and LAG3 gene polymorphisms with hepatocellular carcinoma risk.
Autorzy:: Wei J; College of Pharmacy, Youjiang Medical University for Nationalities, Baise, Guangxi, China.; Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi, China.
Liao Z; College of Pharmacy, Youjiang Medical University for Nationalities, Baise, Guangxi, China. .; Guangxi database construction and application engineering research center for intracorporal pharmacochemistry of TCM, Baise, Guangxi, China. .
Tao Y; Basic Medical College, Youjiang Medical University for Nationalities, Baise, Guangxi, China.
Liu S; Basic Medical College, Youjiang Medical University for Nationalities, Baise, Guangxi, China.; Pokaż więcej
Źródło:: BMC medical genomics [BMC Med Genomics] 2023 May 02; Vol. 16 (1), pp. 92. Date of Electronic Publication: 2023 May 02.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Carcinoma, Hepatocellular*/genetics
Carcinoma, Hepatocellular*/pathology
Liver Neoplasms*/genetics
Liver Neoplasms*/pathology
Lymphocyte Activation Gene 3 Protein*/genetics
Programmed Cell Death 1 Receptor*/genetics
Humans ; alpha-Fetoproteins ; Case-Control Studies ; Gene Frequency ; Genetic Predisposition to Disease ; Genotype ; Lymphocytes/pathology ; Polymorphism, Single Nucleotide

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world study.
Autorzy:: Chang X; Department of Interventional Therapy II, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Li X; Department of Oncology, Central Hospital Affiliated to Shandong First Medical University, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Sun P; Department of Interventional Therapy II, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Li Z; Department of Interventional Therapy II, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Sun P; Department of Hepatological Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, 250117, Jinan, Shandong, China. .
Ning S; Department of Interventional Therapy I, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, 250117, Jinan, Shandong, China. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2024 Apr 16; Vol. 24 (1), pp. 480. Date of Electronic Publication: 2024 Apr 16.
Typ publikacji:: Journal Article
MeSH Terms:: Carcinoma, Hepatocellular*/drug therapy
Liver Neoplasms*/drug therapy
Phenylurea Compounds*
Quinolines*
Humans ; Programmed Cell Death 1 Receptor ; Retrospective Studies

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: PD-1/PD-L1 axis induced host immunosuppression via PI3K/Akt/mTOR signalling pathway in piglets infected by Glaesserella Parasuis.
Autorzy:: Li J; Hubei Key Laboratory of Animal Nutrition and Feed Science, Wuhan Polytechnic University, Wuhan, 430023, PR China.; Hubei Collaborative Innovation Center for Animal Nutrition and Feed Safety, Wuhan, 430023, PR China.
Liu S; Hubei Key Laboratory of Animal Nutrition and Feed Science, Wuhan Polytechnic University, Wuhan, 430023, PR China.; Hubei Collaborative Innovation Center for Animal Nutrition and Feed Safety, Wuhan, 430023, PR China.
Dong Q; Hubei Key Laboratory of Animal Nutrition and Feed Science, Wuhan Polytechnic University, Wuhan, 430023, PR China.; Hubei Collaborative Innovation Center for Animal Nutrition and Feed Safety, Wuhan, 430023, PR China.
Fu Y; Hubei Key Laboratory of Animal Nutrition and Feed Science, Wuhan Polytechnic University, Wuhan, 430023, PR China.; Hubei Collaborative Innovation Center for Animal Nutrition and Feed Safety, Wuhan, 430023, PR China.
Sun Y; Hubei Key Laboratory of Animal Nutrition and Feed Science, Wuhan Polytechnic University, Wuhan, 430023, PR China.; Hubei Collaborative Innovation Center for Animal Nutrition and Feed Safety, Wuhan, 430023, PR China.
Luo R; Hubei Key Laboratory of Animal Nutrition and Feed Science, Wuhan Polytechnic University, Wuhan, 430023, PR China.; Hubei Collaborative Innovation Center for Animal Nutrition and Feed Safety, Wuhan, 430023, PR China.
Tian X; Hubei Key Laboratory of Animal Nutrition and Feed Science, Wuhan Polytechnic University, Wuhan, 430023, PR China.; Hubei Collaborative Innovation Center for Animal Nutrition and Feed Safety, Wuhan, 430023, PR China.
Guo L; Hubei Key Laboratory of Animal Nutrition and Feed Science, Wuhan Polytechnic University, Wuhan, 430023, PR China.; Hubei Collaborative Innovation Center for Animal Nutrition and Feed Safety, Wuhan, 430023, PR China.
Liu W; Hubei Key Laboratory of Animal Nutrition and Feed Science, Wuhan Polytechnic University, Wuhan, 430023, PR China.; Hubei Collaborative Innovation Center for Animal Nutrition and Feed Safety, Wuhan, 430023, PR China.
Qiu Y; Hubei Key Laboratory of Animal Nutrition and Feed Science, Wuhan Polytechnic University, Wuhan, 430023, PR China.; Hubei Collaborative Innovation Center for Animal Nutrition and Feed Safety, Wuhan, 430023, PR China.
Lu Q; Hubei Key Laboratory of Animal Nutrition and Feed Science, Wuhan Polytechnic University, Wuhan, 430023, PR China.; Hubei Collaborative Innovation Center for Animal Nutrition and Feed Safety, Wuhan, 430023, PR China.
Ye C; Hubei Key Laboratory of Animal Nutrition and Feed Science, Wuhan Polytechnic University, Wuhan, 430023, PR China.; Hubei Collaborative Innovation Center for Animal Nutrition and Feed Safety, Wuhan, 430023, PR China.
Zong B; Hubei Key Laboratory of Animal Nutrition and Feed Science, Wuhan Polytechnic University, Wuhan, 430023, PR China.; Hubei Collaborative Innovation Center for Animal Nutrition and Feed Safety, Wuhan, 430023, PR China.
Fu S; Hubei Key Laboratory of Animal Nutrition and Feed Science, Wuhan Polytechnic University, Wuhan, 430023, PR China. .; Hubei Collaborative Innovation Center for Animal Nutrition and Feed Safety, Wuhan, 430023, PR China. .; Pokaż więcej
Źródło:: BMC veterinary research [BMC Vet Res] 2024 Apr 06; Vol. 20 (1), pp. 141. Date of Electronic Publication: 2024 Apr 06.
Typ publikacji:: Randomized Controlled Trial, Veterinary; Journal Article
MeSH Terms:: Haemophilus parasuis*
Haemophilus Infections*/microbiology
Haemophilus Infections*/veterinary
Swine Diseases*/microbiology
Animals ; Swine ; Proto-Oncogene Proteins c-akt ; Programmed Cell Death 1 Receptor ; Phosphatidylinositol 3-Kinases ; B7-H1 Antigen ; TOR Serine-Threonine Kinases ; Immunosuppression Therapy/veterinary

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: CAR T cells and T cells phenotype and function are impacted by glucocorticoid exposure with different magnitude.
Autorzy:: Poiret T; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. .
Vikberg S; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Schoutrop E; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Mattsson J; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.; Gloria and Seymour Epstein Chair in Cell Therapy and Transplantation, Princess Margaret Cancer Centre and University of Toronto; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Magalhaes I; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.; Department of Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden.; Pokaż więcej
Źródło:: Journal of translational medicine [J Transl Med] 2024 Mar 12; Vol. 22 (1), pp. 273. Date of Electronic Publication: 2024 Mar 12.
Typ publikacji:: Journal Article
MeSH Terms:: T-Lymphocytes*
Receptors, Chimeric Antigen*/metabolism
Glucocorticoids ; Programmed Cell Death 1 Receptor/metabolism ; Immunotherapy, Adoptive ; Phenotype ; Antigens, CD19/metabolism

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy.
Autorzy:: Jin S; School of Life Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Wang H; Henan Key Laboratory of Immunology and Targeted Drugs, School of Medical Technology, Xinxiang Medical University, Xinxiang, Henan, 453003, China.
Li Y; School of Life Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Yang J; School of Life Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Li B; School of Life Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Shi P; School of Life Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Zhang X; School of Life Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Zhou X; School of Life Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Zhou X; School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-Sen University, Shenzhen, 518107, China.
Niu X; School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-Sen University, Shenzhen, 518107, China.
Wu M; School of Life Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Wu Y; School of Life Sciences, Zhengzhou University, Zhengzhou, 450001, China.; International Joint Laboratory for Protein and Peptide Drugs of Henan Province, Zhengzhou University, Zhengzhou, 450001, China.
Zhai W; School of Life Sciences, Zhengzhou University, Zhengzhou, 450001, China.; International Joint Laboratory for Protein and Peptide Drugs of Henan Province, Zhengzhou University, Zhengzhou, 450001, China.
Qi Y; School of Life Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Gao Y; School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-Sen University, Shenzhen, 518107, China. .
Zhao W; School of Life Sciences, Zhengzhou University, Zhengzhou, 450001, China. .; Pokaż więcej
Źródło:: Cell communication and signaling : CCS [Cell Commun Signal] 2024 Mar 11; Vol. 22 (1), pp. 173. Date of Electronic Publication: 2024 Mar 11.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Immune Checkpoint Inhibitors*/pharmacology
Immune Checkpoint Inhibitors*/therapeutic use
Neoplasms*/drug therapy
Neoplasms*/pathology
Animals ; Mice ; Programmed Cell Death 1 Receptor ; CD8-Positive T-Lymphocytes ; CD47 Antigen/metabolism ; B7-H1 Antigen ; Phagocytosis ; Immunotherapy ; Tumor Microenvironment

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: Rab37 mediates trafficking and membrane presentation of PD-1 to sustain T cell exhaustion in lung cancer.
Autorzy:: Kuo WT; Department of Pharmacology, College of Medicine, National Cheng Kung University, No. 1, University Road, Tainan, 701, Taiwan.
Kuo IY; Department of Pharmacology, College of Medicine, National Cheng Kung University, No. 1, University Road, Tainan, 701, Taiwan.; Department of Biotechnology, College of Biomedical Science, Kaohsiung Medical University, Kaohsiung, Taiwan.
Hsieh HC; Institute of Basic Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Wu ST; Department of Pharmacology, College of Medicine, National Cheng Kung University, No. 1, University Road, Tainan, 701, Taiwan.
Su WC; Division of Oncology, Department of Internal Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Wang YC; Department of Pharmacology, College of Medicine, National Cheng Kung University, No. 1, University Road, Tainan, 701, Taiwan. .; Institute of Basic Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan. .; Pokaż więcej
Źródło:: Journal of biomedical science [J Biomed Sci] 2024 Feb 07; Vol. 31 (1), pp. 20. Date of Electronic Publication: 2024 Feb 07.
Typ publikacji:: Journal Article
MeSH Terms:: Lung Neoplasms*/pathology
Monomeric GTP-Binding Proteins*/metabolism
Animals ; Humans ; Mice ; CD8-Positive T-Lymphocytes/metabolism ; Hepatitis A Virus Cellular Receptor 2/metabolism ; Leukocytes, Mononuclear/metabolism ; Mice, Knockout ; Programmed Cell Death 1 Receptor ; rab GTP-Binding Proteins ; T-Cell Exhaustion ; Tumor Microenvironment

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: Lipid alterations play a role in the integration of PD-1/PD-L1 inhibitors and anlotinib for the treatment of advanced non-small-cell lung cancer.
Autorzy:: Liu L; The Second Affiliated Hospital of Soochow University, Suzhou, China.; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.
Zhang S; Zhu Zhou Central Hospital, Zhuzhou, 412007, China.
Yang HY; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.
Zhou CH; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.
Xiong Y; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.
Yang N; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China. .
Tian Y; The Second Affiliated Hospital of Soochow University, Suzhou, China. .; Pokaż więcej
Źródło:: Lipids in health and disease [Lipids Health Dis] 2024 Jan 13; Vol. 23 (1), pp. 16. Date of Electronic Publication: 2024 Jan 13.
Typ publikacji:: Journal Article
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Indoles*
Quinolines*
Humans ; Immune Checkpoint Inhibitors/pharmacology ; Immune Checkpoint Inhibitors/therapeutic use ; Programmed Cell Death 1 Receptor/genetics ; Programmed Cell Death 1 Receptor/metabolism ; Programmed Cell Death 1 Receptor/therapeutic use ; Lipids/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: Combined mitoxantrone and anti-TGFβ treatment with PD-1 blockade enhances antitumor immunity by remodelling the tumor immune landscape in neuroblastoma.
Autorzy:: Lucarini V; Department of Paediatric Haematology/Oncology and of Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, 00146, Rome, Italy.
Melaiu O; Department of Paediatric Haematology/Oncology and of Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, 00146, Rome, Italy.; Department of Clinical Sciences and Translational Medicine, University of Rome 'Tor Vergata', Rome, Italy.
D'Amico S; Department of Paediatric Haematology/Oncology and of Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, 00146, Rome, Italy.
Pastorino F; Laboratory of Experimental Therapies in Oncology, IRCCS Istituto Giannina Gaslini, 16147, Genoa, Italy.
Tempora P; Department of Paediatric Haematology/Oncology and of Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, 00146, Rome, Italy.
Scarsella M; Flow Cytometry Core Facility, Bambino Gesù Children's Hospital, IRCCS, 00146, Rome, Italy.
Pezzullo M; Research Laboratories, Bambino Gesù Children's Hospital, IRCCS, 00146, Rome, Italy.
De Ninno A; CNR Institute for Photonics and Nanotechnology, Rome, 00156, Italy.
D'Oria V; Confocal Microscopy Core Facility, Research Center, Bambino Gesù Children's Hospital, IRCCS, 00146, Rome, Italy.
Cilli M; IRCCS Ospedale Policlinico San Martino, Animal Facility, 16132, Genoa, Italy.
Emionite L; IRCCS Ospedale Policlinico San Martino, Animal Facility, 16132, Genoa, Italy.
Infante P; Department of Molecular Medicine, University La Sapienza, 00161, Rome, Italy.
Di Marcotullio L; Department of Molecular Medicine, University La Sapienza, 00161, Rome, Italy.
De Ioris MA; Department of Paediatric Haematology/Oncology and of Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, 00146, Rome, Italy.
Barillari G; Department of Clinical Sciences and Translational Medicine, University of Rome 'Tor Vergata', Rome, Italy.
Alaggio R; Pathology Unit, Bambino Gesù Children's Hospital, IRCCS, 00146, Rome, Italy.
Businaro L; CNR Institute for Photonics and Nanotechnology, Rome, 00156, Italy.
Ponzoni M; Laboratory of Experimental Therapies in Oncology, IRCCS Istituto Giannina Gaslini, 16147, Genoa, Italy.
Locatelli F; Department of Paediatric Haematology/Oncology and of Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, 00146, Rome, Italy.; Department of Life Sciences and Public Health, Catholic University of the Sacred Heart, 00168, Rome, Italy.
Fruci D; Department of Paediatric Haematology/Oncology and of Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, 00146, Rome, Italy. .; Pokaż więcej
Źródło:: Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2022 Nov 17; Vol. 41 (1), pp. 326. Date of Electronic Publication: 2022 Nov 17.
Typ publikacji:: Journal Article
MeSH Terms:: Programmed Cell Death 1 Receptor*
Neuroblastoma*/drug therapy
Humans ; Mice ; Animals ; Mitoxantrone/pharmacology ; CD8-Positive T-Lymphocytes ; Transforming Growth Factor beta ; Cell Line, Tumor ; Mice, Transgenic ; Tumor Microenvironment

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: A novel computer-assisted tool for 3D imaging of programmed death-ligand 1 expression in immunofluorescence-stained and optically cleared breast cancer specimens.
Autorzy:: Lee YH; Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan.
Huang CY; Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan.
Hsieh YH; JelloX Biotech Inc, Hsinchu, Taiwan.
Yang CH; JelloX Biotech Inc, Hsinchu, Taiwan.
Hung YL; JelloX Biotech Inc, Hsinchu, Taiwan.
Chen YA; JelloX Biotech Inc, Hsinchu, Taiwan.
Lin YC; JelloX Biotech Inc, Hsinchu, Taiwan.
Lin CH; Department of Medical Oncology, Cancer Center Branch, National Taiwan University Hospital, Taipei, Taiwan.; Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
Lee JH; Department of Oncology, National Taiwan University Hospital, Hsin-Chu Branch, Hsinchu, Taiwan.
Wang MY; Department of Surgical Oncology, Cancer Center Branch, National Taiwan University Hospital, Taipei, Taiwan.
Kuo WH; Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan.
Lin YY; JelloX Biotech Inc, Hsinchu, Taiwan.
Lu YS; Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan. .; Department of Oncology, National Taiwan University Hospital, No.7, Chung Shan S. Rd., Zhongzheng Dist, Taipei, 100225, Taiwan. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2024 Jan 24; Vol. 24 (1), pp. 121. Date of Electronic Publication: 2024 Jan 24.
Typ publikacji:: Journal Article
MeSH Terms:: B7-H1 Antigen*
Breast Neoplasms*
Humans ; Female ; Imaging, Three-Dimensional ; Immune Checkpoint Inhibitors ; Ligands ; Programmed Cell Death 1 Receptor ; Coloring Agents ; Computers

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors.
Autorzy:: Wang J; Department of Oncology, Beijing Friendship Hospital, Capital Medical University, #95 Yong An Road, Xicheng District, Beijing, China.
Ma Y; Radiotherapy Department, Shijingshan Teaching Hospital of Capital Medical University Beijing, #24 Shijingshan Road, Shijingshan District, Beijing, 100040, China.
Lin H; Department of Oncology, Beijing Friendship Hospital, Capital Medical University, #95 Yong An Road, Xicheng District, Beijing, China.
Wang J; Department of Oncology, Beijing Friendship Hospital, Capital Medical University, #95 Yong An Road, Xicheng District, Beijing, China. .
Cao B; Department of Oncology, Beijing Friendship Hospital, Capital Medical University, #95 Yong An Road, Xicheng District, Beijing, China. .; Pokaż więcej
Źródło:: BMC immunology [BMC Immunol] 2024 Jan 24; Vol. 25 (1), pp. 8. Date of Electronic Publication: 2024 Jan 24.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Pneumonia*
Neoplasms*/drug therapy
Humans ; Female ; Immune Checkpoint Inhibitors/adverse effects ; Cardiotoxicity ; Programmed Cell Death 1 Receptor ; Retrospective Studies ; Anti-Bacterial Agents ; Biomarkers

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: Spatial and temporal heterogeneity of tumor immune microenvironment between primary tumor and brain metastases in NSCLC.
Autorzy:: Liu JS; Department of Neurosurgery, Zhongnan Hospital of Wuhan University, 430062, Wuhan, China.
Cai YX; Department of Pathology, Zhongnan Hospital of Wuhan University, 430062, Wuhan, China.
He YZ; Department of Neurosurgery, Zhongnan Hospital of Wuhan University, 430062, Wuhan, China.
Xu J; Department of Pathology, Zhongnan Hospital of Wuhan University, 430062, Wuhan, China.
Tian SF; Department of Pathology, Zhongnan Hospital of Wuhan University, 430062, Wuhan, China. .
Li ZQ; Department of Neurosurgery, Zhongnan Hospital of Wuhan University, 430062, Wuhan, China. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2024 Jan 24; Vol. 24 (1), pp. 123. Date of Electronic Publication: 2024 Jan 24.
Typ publikacji:: Journal Article
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*
Lung Neoplasms*
Brain Neoplasms*
Adenocarcinoma of Lung*
Humans ; B7-H1 Antigen ; CTLA-4 Antigen ; Programmed Cell Death 1 Receptor ; Tumor Microenvironment

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 17.

Tytuł:: Gut microbiome for predicting immune checkpoint blockade-associated adverse events.
Autorzy:: Hu M; State Key Laboratory of Systems Medicine for Cancer, NHC Key Laboratory of Digestive Diseases, Division of Gastroenterology and Hepatology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai Cancer Institute, Shanghai, 200001, China.
Lin X; Department of Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.
Sun T; State Key Laboratory of Systems Medicine for Cancer, NHC Key Laboratory of Digestive Diseases, Division of Gastroenterology and Hepatology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai Cancer Institute, Shanghai, 200001, China.
Shao X; Department of Medical Oncology, Xuzhou Central Hospital, Clinical School of Xuzhou Medical University, Xuzhou, 221009, China.
Huang X; State Key Laboratory of Systems Medicine for Cancer, NHC Key Laboratory of Digestive Diseases, Division of Gastroenterology and Hepatology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai Cancer Institute, Shanghai, 200001, China.
Du W; Department of Medical Oncology, Xuzhou Central Hospital, Clinical School of Xuzhou Medical University, Xuzhou, 221009, China.
Guo M; Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China.
Zhu X; State Key Laboratory of Systems Medicine for Cancer, NHC Key Laboratory of Digestive Diseases, Division of Gastroenterology and Hepatology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai Cancer Institute, Shanghai, 200001, China.
Zhou Y; State Key Laboratory of Systems Medicine for Cancer, NHC Key Laboratory of Digestive Diseases, Division of Gastroenterology and Hepatology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai Cancer Institute, Shanghai, 200001, China.
Tong T; State Key Laboratory of Systems Medicine for Cancer, NHC Key Laboratory of Digestive Diseases, Division of Gastroenterology and Hepatology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai Cancer Institute, Shanghai, 200001, China.
Guo F; Department of Gastroenterology, the First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, 310003, China.
Han T; Department of Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.
Wu X; Department of Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.
Shi Y; Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders, Shanghai Jiao Tong University, 1954 Huashan Road, Shanghai, 200030, China.
Xiao X; Department of Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China. .
Zhang Y; Department of Medical Oncology, Xuzhou Central Hospital, Clinical School of Xuzhou Medical University, Xuzhou, 221009, China. .
Hong J; State Key Laboratory of Systems Medicine for Cancer, NHC Key Laboratory of Digestive Diseases, Division of Gastroenterology and Hepatology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai Cancer Institute, Shanghai, 200001, China. .
Chen H; State Key Laboratory of Systems Medicine for Cancer, NHC Key Laboratory of Digestive Diseases, Division of Gastroenterology and Hepatology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai Cancer Institute, Shanghai, 200001, China. .; Pokaż więcej
Źródło:: Genome medicine [Genome Med] 2024 Jan 19; Vol. 16 (1), pp. 16. Date of Electronic Publication: 2024 Jan 19.
Typ publikacji:: Journal Article
MeSH Terms:: Neoplasms*/drug therapy
Gastrointestinal Microbiome*
Antineoplastic Agents, Immunological*/therapeutic use
Drug-Related Side Effects and Adverse Reactions*
Immune System Diseases*
Lung Neoplasms*/drug therapy
Humans ; Immune Checkpoint Inhibitors/therapeutic use ; RNA, Ribosomal, 16S/genetics ; Vitamin K 2/therapeutic use ; Immunotherapy/adverse effects ; Programmed Cell Death 1 Receptor ; Retrospective Studies

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 18.

Tytuł:: Paclitaxel liposome (Lipusu) based chemotherapy combined with immunotherapy for advanced non-small cell lung cancer: a multicenter, retrospective real-world study.
Autorzy:: Li R; Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, 100044, Beijing, China.
Liang H; Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, 100044, Beijing, China.
Li J; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, 210029, Nanjing, China.
Shao Z; Department of Radiation Oncology, Qilu Hospital of Shandong University, 250012, Jinan, China.
Yang D; Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, 100044, Beijing, China.
Bao J; Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, 100044, Beijing, China.
Wang K; Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, 100044, Beijing, China.
Xi W; Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, 100044, Beijing, China.
Gao Z; Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, 100044, Beijing, China.
Guo R; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, 210029, Nanjing, China.
Mu X; Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, 100044, Beijing, China. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2024 Jan 18; Vol. 24 (1), pp. 107. Date of Electronic Publication: 2024 Jan 18.
Typ publikacji:: Multicenter Study; Journal Article
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/pathology
Adenocarcinoma*/drug therapy
Carcinoma, Squamous Cell*/drug therapy
Humans ; Paclitaxel ; Liposomes ; Immune Checkpoint Inhibitors/adverse effects ; Programmed Cell Death 1 Receptor/therapeutic use ; Retrospective Studies ; Immunotherapy/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 19.

Tytuł:: Role of thymosin α1 in restoring immune response in immunological nonresponders living with HIV.
Autorzy:: Chen C; Shanghai Public Health Clinical Center, Fudan University, Caolang Road 2901, Jinshan, Shanghai, 201508, China.
Wang J; Shanghai Public Health Clinical Center, Fudan University, Caolang Road 2901, Jinshan, Shanghai, 201508, China.
Xun J; Shanghai Public Health Clinical Center, Fudan University, Caolang Road 2901, Jinshan, Shanghai, 201508, China.
Zhang X; Shanghai Public Health Clinical Center, Fudan University, Caolang Road 2901, Jinshan, Shanghai, 201508, China.
Liu L; Shanghai Public Health Clinical Center, Fudan University, Caolang Road 2901, Jinshan, Shanghai, 201508, China.
Song Z; Shanghai Public Health Clinical Center, Fudan University, Caolang Road 2901, Jinshan, Shanghai, 201508, China.
Zhang R; Shanghai Public Health Clinical Center, Fudan University, Caolang Road 2901, Jinshan, Shanghai, 201508, China.
Chen J; Shanghai Public Health Clinical Center, Fudan University, Caolang Road 2901, Jinshan, Shanghai, 201508, China. .
Lu H; Shanghai Public Health Clinical Center, Fudan University, Caolang Road 2901, Jinshan, Shanghai, 201508, China. .; National Clinical Research Centre for Infectious Diseases, The Third People' s Hospital of Shenzhen, The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, 518112, China. .; Pokaż więcej
Źródło:: BMC infectious diseases [BMC Infect Dis] 2024 Jan 17; Vol. 24 (1), pp. 97. Date of Electronic Publication: 2024 Jan 17.
Typ publikacji:: Journal Article
MeSH Terms:: Hepatitis A Virus Cellular Receptor 2*
HIV Infections*/drug therapy
Humans ; Male ; Female ; Adult ; Middle Aged ; Thymalfasin/therapeutic use ; Programmed Cell Death 1 Receptor ; Prospective Studies ; CD4-Positive T-Lymphocytes ; CD4 Lymphocyte Count ; Immunity

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 20.

Tytuł:: Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study.
Autorzy:: Qin B; Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, 4th West Ring Road 100, Fengtai district, 100039, Beijing, China.
Xin L; Department of Gynaecology and Obstetrics, PLA Rocket Force Characteristic Medical Center, Xinjiekou outer Street 16, Xicheng district, 100088, Beijing, China.; Department of Graduate Administration, PLA General Hospital, Fuxing Road 28, Haidian district, 100853, Beijing, China.
Liang C; Medical Service Department, PLA General Hospital, Fuxing Road 28, Haidian district, 100853, Beijing, China.
Li L; Department of Graduate Administration, PLA General Hospital, Fuxing Road 28, Haidian district, 100853, Beijing, China.
Song Q; Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, 4th West Ring Road 100, Fengtai district, 100039, Beijing, China.
Long Y; Department of Graduate Administration, PLA General Hospital, Fuxing Road 28, Haidian district, 100853, Beijing, China.
Zhang X; Department of Oncology, The First Medical Center of PLA General Hospital, Fuxing Road 28, Haidian district, 100853, Beijing, China.
Wang D; Department of Oncology, The First Medical Center of PLA General Hospital, Fuxing Road 28, Haidian district, 100853, Beijing, China.
Shi W; Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, 4th West Ring Road 100, Fengtai district, 100039, Beijing, China.
Zhang J; Department of Oncology, The First Medical Center of PLA General Hospital, Fuxing Road 28, Haidian district, 100853, Beijing, China.
Hu Y; Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, 4th West Ring Road 100, Fengtai district, 100039, Beijing, China. .
Yang B; Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, 4th West Ring Road 100, Fengtai district, 100039, Beijing, China. .
Xiong Q; Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, 4th West Ring Road 100, Fengtai district, 100039, Beijing, China. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2024 Jan 17; Vol. 24 (1), pp. 100. Date of Electronic Publication: 2024 Jan 17.
Typ publikacji:: Multicenter Study; Journal Article
MeSH Terms:: Lung Neoplasms*/drug therapy
Small Cell Lung Carcinoma*/drug therapy
Humans ; B7-H1 Antigen ; Immune Checkpoint Inhibitors/adverse effects ; Programmed Cell Death 1 Receptor ; Retrospective Studies

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Programmed Cell Death 1 Receptor"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Publikacja

Język